BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29987021)

  • 1. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
    Banerjee S; Ji C; Mayfield JE; Goel A; Xiao J; Dixon JE; Guo X
    Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8155-8160. PubMed ID: 29987021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
    Banerjee S; Wei T; Wang J; Lee JJ; Gutierrez HL; Chapman O; Wiley SE; Mayfield JE; Tandon V; Juarez EF; Chavez L; Liang R; Sah RL; Costello C; Mesirov JP; de la Vega L; Cooper KL; Dixon JE; Xiao J; Lei X
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24881-24891. PubMed ID: 31754034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
    Guo X; Wang X; Wang Z; Banerjee S; Yang J; Huang L; Dixon JE
    Nat Cell Biol; 2016 Feb; 18(2):202-12. PubMed ID: 26655835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
    Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
    Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging roles of DYRK2 in cancer.
    Tandon V; de la Vega L; Banerjee S
    J Biol Chem; 2021; 296():100233. PubMed ID: 33376136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
    Liu L; Fu Y; Zheng Y; Ma M; Wang C
    Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin.
    Yoon MJ; Kang YJ; Lee JA; Kim IY; Kim MA; Lee YS; Park JH; Lee BY; Kim IA; Kim HS; Kim SA; Yoon AR; Yun CO; Kim EY; Lee K; Choi KS
    Cell Death Dis; 2014 Mar; 5(3):e1112. PubMed ID: 24625971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.
    Milacic V; Banerjee S; Landis-Piwowar KR; Sarkar FH; Majumdar AP; Dou QP
    Cancer Res; 2008 Sep; 68(18):7283-92. PubMed ID: 18794115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-κB inhibition and p53 reactivation in human lung cancer cells.
    Zhou B; Zuo Y; Li B; Wang H; Liu H; Wang X; Qiu X; Hu Y; Wen S; Du J; Bu X
    Mol Cancer Ther; 2013 Aug; 12(8):1381-92. PubMed ID: 23696216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
    Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
    Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of HSF1 and DYRK2 impedes cancer progression.
    Tandon V; Moreno R; Allmeroth K; Quinn J; Wiley SE; Nicely LG; Denzel MS; Edwards J; de la Vega L; Banerjee S
    Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36622366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative.
    Chakraborty MP; Bhattacharyya S; Roy S; Bhattacharya I; Das R; Mukherjee A
    J Biol Chem; 2021; 296():100449. PubMed ID: 33617879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment.
    Hasima N; Aggarwal BB
    Curr Med Chem; 2014; 21(14):1583-94. PubMed ID: 23834173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
    Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
    Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
    Correa-Sáez A; Jiménez-Izquierdo R; Garrido-Rodríguez M; Morrugares R; Muñoz E; Calzado MA
    Cell Mol Life Sci; 2020 Dec; 77(23):4747-4763. PubMed ID: 32462403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
    Mimoto R; Taira N; Takahashi H; Yamaguchi T; Okabe M; Uchida K; Miki Y; Yoshida K
    Cancer Lett; 2013 Oct; 339(2):214-25. PubMed ID: 23791882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arene-Ru(II) complexes of curcumin exert antitumor activity via proteasome inhibition and apoptosis induction.
    Bonfili L; Pettinari R; Cuccioloni M; Cecarini V; Mozzicafreddo M; Angeletti M; Lupidi G; Marchetti F; Pettinari C; Eleuteri AM
    ChemMedChem; 2012 Nov; 7(11):2010-20. PubMed ID: 22997162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation.
    Jiang YS; Lei JA; Feng F; Liang QM; Wang FR
    Acta Pharmacol Sin; 2014 Dec; 35(12):1556-65. PubMed ID: 25399650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.